Why the study?
To better understand Ewing sarcoma by contrasting the standard-of-care systemic therapy evolution with the molecular biology understanding, and to highlight the need for subtype-specific therapeutic plans.
This review summarizes a century of clinical and scientific progress in understanding and treating Ewing sarcoma and related small round blue cell tumors.
Answers are grounded in this paper and cite their sources.
Broadens diagnostic considerations in atypical bone tumors; extends Ewing spectrum but remains hypothesis-generating.
The year 2021 marked the centenary of the first publication of a cancer termed diffuse endothelioma of bone by James Ewing. Its unique features were apparent even in the first case series he described. This new diagnosis was clearly distinct from osteogenic sarcoma and myeloma, which were already well recognized at the time. We undertake this summary to better understanding Ewing sarcoma, contrasting the logarithmic evolution of the standard of care of systemic therapy for this and related diagnoses to the exponential understanding of the molecular biology of this family of tumors. We also outline in this manuscript how the finding of genomic relatives within Ewing sarcoma itself and related tumors, first noted nearly 40 years ago, helps us appreciate the need to find therapeutic plans that are specific for each small round blue cell tumor subtype. The advent of next generation sequencing regarding previously unknown small round blue cell tumor subtypes in many ways puts us back in the shoes of James Ewing in 1921, searching anew for clues leading to better treatments for increasingly rare cancer subsets.
No takes yet. Share an insight, caveat, or question.
Maki et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: